Blood clots and bleeding during blood thinner treatment in people with cancer
Looks at clots and bleeding in adults with cancer taking blood thinners.
Key facts
- Who runs it
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Where
- Italy2 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Thromboembolic and Hemorrhagic Complications of Anticoagulant Treatment in Patients With CAT
- Status
- Recruiting
- People taking part
- 1,000 people, planned
- Started
- 2 Jan 2016
- Expected to end
- 31 Dec 2027
- Type of study
- Observational
- Record updated
- 4 December 2024
Who can take part
The trial is looking for adults with cancer who have a blood clot in a vein or in the lungs. It follows how they do on blood-thinning treatment.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- A blood clot in a vein at any site, including a clot linked to a central venous catheter (CVC), or a clot in the lungs (pulmonary embolism), with or without symptoms. People must also have a solid or blood cancer that is active or being treated.
- Earlier treatment
- People are treated with low molecular weight heparin or direct oral anticoagulants (DOACs), as decided by their doctor.
Show the full registry criteria (7)Hide the full registry criteria
Who can take part
- Age ≥ 18 years
- Diagnosis of venous thrombosis at any site
- Diagnosis of CVC-related venous thrombosis
- Diagnosis of pulmonary embolism, both symptomatic and incidental
- Diagnosis of solid or hematological neoplasm, either under treatment or active
- Obtaining of Informed Consent
Who cannot take part
- None
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Venous thromboembolism
This trial is currently available in Italy.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The study is classified as an observational pharmacological study, spontaneous, monocentric, and both retrospective and prospective for adult patients with a diagnosis of venous thromboembolism in the context of neoplasia, followed at the SSD Angiology and Coagulation Disorders of the IRCCS Azienda Ospedaliero-Universitaria di Bologna and The Cardiovascular Medicine Department, specifically the Angiology Unit, of the IRCCS Arcispedale S. Maria Nuova in Reggio Emilia, from 01/01/2016 to 30/06/2027. The study, including data analysis, is expected to conclude by 31/12/2027.
Read full original descriptionShow less
Patients were treated according to clinical practice, in accordance with the physician's judgment and the information provided in the product's technical datasheet for any concomitant therapies administered as per clinical practice.
The primary objective of the study is to evaluate the frequency of thrombotic and hemorrhagic complications during treatment with low molecular weight heparin or direct oral anticoagulants in patients with venous thromboembolism and solid and hematological neoplasms attending outpatient care at the SSD Angiology and Coagulation Disorders of the IRCCS AOUBO and The Cardiovascular Medicine Department, specifically the Angiology Unit, of the IRCCS Arcispedale S. Maria Nuova in Reggio Emilia, following the initiation of anticoagulant therapy (LMWH or DOACs).
The secondary objectives of the study are:
* To identify risk factors for hemorrhagic complications and bleeding risk during anticoagulant treatment for CAT; * To assess the applicability and reliability of a score, which is not currently in use in clinical practice, without impacting the care process and clinical decisions, in a prospective cohort of patients with CAT.
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Thromboembolic and Hemorrhagic Complications of Anticoagulant Treatment in Patients With CAT (Cancer Associated Thrombosis)
- Plain-language title
- Blood clots and bleeding during blood thinner treatment in people with cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT06714734, who can take part
- Record updated
- 4 December 2024